Shkreli Loses Bid To Nix Charges After Resting Case

By Stewart Bishop · July 26, 2017, 7:00 PM EDT

Attorneys for former Turing Pharmaceuticals and Retrophin CEO Martin Shkreli on Wednesday rested their case without calling any witnesses to testify at his securities fraud trial over allegations he defrauded investors...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Case Information

Case Title

USA v. Shkreli et al

Case Number

Court

New York Eastern

Nature of Suit

Date Filed

December 14, 2015

Recent Articles By Stewart

August 02, 2024
2nd Circ. Backs Conviction Over Fake-Therapy Scheme
March 08, 2024
DOJ Eyes FCPA For New Whistleblower Rewards Program
March 06, 2024
Ex-Stimwave CEO Found Guilty Of Healthcare Fraud
March 04, 2024
Trial Of Ex-Stimwave CEO Over Medical Device Nears End
February 29, 2024
Bankrupt Endo To Pay $465M To Resolve Opioid Claims
September 18, 2023
NYC Atty Admits To Bilking Clients, Laundering Fraud Funds
July 14, 2023
Colombo Family Union Shakedown Case Nets Final Plea
March 10, 2023
Ex-Congressman Stephen Buyer Convicted Of Insider Trading
March 09, 2023
Ex-Congressman Says Feds' Insider Trading Rap Is Weak
March 08, 2023
Ex-US Rep. Takes Stand, Denies Trading On Secret M&A Info